Veterans and psychedelics event at RAND examines policy, clinical evidence, and implementation challenges for psychedelic-assisted care in military and veteran settings

Veterans and psychedelics are the focus of a RAND event centered on how psychedelic-assisted care may affect military and veteran populations. The subject combines clinical evidence, policy questions, and practical implementation issues that shape access, safety, and oversight. Military service members and veterans face high rates of PTSD, depression, and related mental health challenges, making treatments such as MDMA-assisted therapy and psilocybin-based care especially relevant. Key questions likely include what current evidence supports these approaches, how regulation and federal policy affect rollout, and what institutions would need to deliver care responsibly. RAND's involvement points to a policy-oriented discussion that connects research findings with real-world systems such as the VA, health care providers, and public decision makers. The broader significance lies in whether psychedelic treatment models can move from promising trials into accountable, equitable veteran care.